Intravenous immune globulin 2 g/kg,
does it really help with Clinical improvement including strength and function in active adult dermatomyositis?
research showsThe grade is C with 50 points. In ProDERM, a TIS response of at least 20 points at week 16 occurred in 37/47 (79%) with IVIG versus 21/48 (44%) with placebo, an absolute difference of 35 points (95% CI 17 to 53; P<.001). Twenty points is the minimal-improvement threshold in the 2016 ACR/EULAR adult myositis response criteria, supporting a meaningful effect. The evidence is one 95-person Octapharma trial, and six thromboembolic events occurred with IVIG.
ads claimThe 79% response is not a cure rate. It is the proportion reaching minimal improvement on a composite of clinical and laboratory components.
Useful facts when choosing a product
- IVIG is a prescription biologic prepared from pooled donor plasma immunoglobulin.
- ProDERM administered 2 g/kg every four weeks and assessed a 16-week blinded period.
- NCT02728752 prespecified a TIS response of at least 20.
What the research actually shows
This double-blind placebo-controlled phase 3 trial at 36 North American and European centers assigned 95 adults with active dermatomyositis to IVIG, 47, or placebo, 48. The week-16 primary set included randomized participants who received at least one infusion. Enrollment below 200 was counted as one design limitation. NCT02728752 and the protocol prespecified a TIS response of at least 20 as the primary endpoint. Octapharma Pharmazeutika designed and conducted the trial, collected and analyzed data, supplied IVIG and placebo, and funded medical writing.
Why this is classified as C (50)
A large response difference at a validated minimal-improvement threshold is limited by one 95-person manufacturer trial, giving C with 50 points.
Counterpoint. Thromboembolic events occurred despite exclusion of patients with major thrombotic risk, making individual risk assessment important in practice.
Rejudgment record. Cross-check applied — Cross-checked ProDERM, its protocol, and NCT02728752 for the TIS threshold, 95-person analysis, Octapharma role, and thromboembolic events
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Minimal clinical improvement at week 16 | C | TIS response was 79% versus 44%. |
| Uniform improvement across all strength components | D | Mean MMT-8 change did not show a clear between-group difference. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | 36-center double-blind placebo-controlled phase 3 randomized trial | 48 | Funded, designed, and analyzed by Octapharma Pharmazeutika | TIS response of at least 20 points at week 16 | 37/47 (79%) versus 21/48 (44%), difference 35 points (95% CI 17 to 53), P<.001; six thromboembolic events with IVIG | Small manufacturer-funded confirmatory trial with a large response difference |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Intravenous immune globulin 2 g/kg x functional improvement in adult dermatomyositis — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/ivig-adult-dermatomyositis-functional-improvement/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.